TREATMENT SATISFACTION IN PATIENTS WITH ATRIAL FIBRILLATION ON NEW ORAL ANTICOAGULANTS AS MEASURED WITH PACT-Q2- PREFER IN AF REGISTRY

Author(s)

Brüggenjürgen B*1;Ammentorp B2;Darius H3;De Caterina R4;Le-Heuzey JY5;Pittrow D6;Reimitz PE2;Schilling RJ7;Schwertfeger M2;Zamorano JL8, Kirchhof P9 1Steinbeis-University-Berlin GmbH, Berlin, Germany, 2Daiichi Sankyo Europe, Munich, Germany, 3Vivantes Klinikum, Berlin, Germany, 4G. d'Annunzio University, Chieti, Italy, 5Georges Pompidou Hospital, René Descartes University, Paris, France, 6Technical University Dresden, Dresden, Germany, 7Barts and St Thomas Hospital, London, United Kingdom, 8University Hospital Ramón y Cajal, Madrid, Spain, 9University of Birmingham Centre for Cardiovascular Sciences and SWBH NHS Trust, Birmingham, United Kingdom

OBJECTIVES: The great majority of patients with atrial fibrillation (AF) require anticoagulation in order to prevent strokes or other thromboembolic events. We aimed at obtaining detailed and current information on patients’ satisfaction with their ongoing anticoagulation treatment. METHODS: PREFER in AF (The PREvention oF thromboembolic events – European Registry in Atrial Fibrillation) is a current non-interventional study performed in France, Germany, Austria, Switzerland, Italy, Spain and UK.  A total of 7243 consecutive patients with ECG-confirmed AF in the previous 12 months are followed up prospectively. The 'Perception of Anticoagulant Treatment Questionnaire' is a valid and reliable instrument that allows the assessment of patients' expectations (PACT-Q1)  and satisfaction regarding anticoagulant treatment, as well as patients’ opinion about treatment convenience of use (PACT-Q2). RESULTS: A total of 5049 patients (69.7%) received antithrombotic treatment and were willing to fill out the PACT-Q2 questionnaire at baseline. 77.1% of these were on vitamin K antagonists (VKAs), 6.4% on new oral anticoagulants (NOACs), 5.2% on antiplatelets (AP) and 11.0% on VKA+AP combinations.  In the “convenience” dimension, the overall score (0-100 range) was 82.9 ±17.3. The score was higher in the NOAC group (88.1 ± 13.0) compared to the VKA (82.1 ± 17.5), AP (87.0 ± 17.9) or VKA +AP groups (83.2 ± 16.8), respectively.   In the “anticoagulant treatment satisfaction” dimension of the PACT-Q2, the overall score was 63.4 ±15.9. Again, this score was higher in the NOAC group (66.6 ±16.6) compared to the VKA (63.2 ±15.9), AP (63.7 ±16.8), or VKA + AP groups (62.8 ±15.0), respectively. CONCLUSIONS: Overall, patients on current anticoagulation achieve relatively high values on the convenience scale, but moderate values on the satisfaction scale. While differences in group size and patient characteristics need to be taken into account, patients on NOACs compared to patients on VKAs tend to rate their convenience and treatment satisfaction higher.

Conference/Value in Health Info

2013-11, ISPOR Europe 2013, The Convention Centre Dublin

Value in Health, Vol. 16, No. 7 (November 2013)

Code

PCV140

Topic

Patient-Centered Research

Topic Subcategory

Stated Preference & Patient Satisfaction

Disease

Cardiovascular Disorders, Respiratory-Related Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×